Trapoxin A Analogue as a Selective Nanomolar Inhibitor of HDAC11
- ACS Chem Biol. 2023 Apr 21;18(4):803-809. doi: 10.1021/acschembio.2c00840.
- 1. Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853, United States.
- 2. Department of Biochemistry & Molecular Medicine, School of Medicine & Health Sciences, George Washington Cancer Center, George Washington University, Washington, District of Columbia 20037, United States.
- 3. Howard Hughes Medical Institute, Cornell University, Ithaca, New York 14853, United States.
Histone deacetylases (HDACs) are Enzymes that regulate many important biological pathways. There is a need for the development of isoform-selective HDAC inhibitors for further biological applications. Here, we report the development of trapoxin A analogues as potent and selective inhibitors of HDAC11, an enzyme that can efficiently remove long-chain fatty acyl groups from proteins. In particular, we show that one of the trapoxin A analogues, TD034, has nanomolar potency in enzymatic assays. We show that in cells, TD034 is active at low micromolar concentrations and inhibits the defatty acylation of SHMT2, a known HDAC11 substrate. The high potency and selectivity of TD034 would permit further development of HDAC11 inhibitors for biological and therapeutic applications.